merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>The vials are significantly cheaper than Zepbound pens and are positioned as a safer alternative to compounded drugs, which are subject to less oversight.</answer>

<question_number>2</question_number>
<answer>By offering Zepbound vials through LillyDirect, Eli Lilly bypasses third-party supply chains and directly connects patients with providers, reducing reliance on telehealth companies that offer compounded medications.</answer>

<question_number>3</question_number>
<answer>Compounded drugs are subject to far less oversight than FDA-approved medications, raising concerns about safety, quality, and effectiveness.</answer>

<question_number>4</question_number>
<answer>By offering a lower-cost alternative, Eli Lilly aims to attract patients who might otherwise turn to compounded drugs, even if it means some patients switch from its more expensive pens.</answer>

<question_number>5</question_number>
<answer>Once tirzepatide is removed from the FDA's shortage list, compounding pharmacies will no longer be legally allowed to produce alternative versions of the medication.</answer>

<question_number>6</question_number>
<answer>It reflects a trend of pharmaceutical companies selling directly to consumers by eliminating third-party supply chain entities and offering transparent pricing.</answer>

<question_number>7</question_number>
<answer>It may lead to increased use of Zepbound vials by Medicare patients, despite concerns about risks such as muscle loss in older individuals.</answer>

<question_number>8</question_number>
<answer>By positioning its vials as a safer alternative, Eli Lilly may influence patients to perceive compounded tirzepatide as riskier due to its lack of FDA oversight.</answer>

<question_number>9</question_number>
<answer>Tirzepatide is currently on the FDA's shortage list, allowing compounding pharmacies to legally produce alternative versions.</answer>

<question_number>10</question_number>
<answer>Lowering the price of Zepbound vials to compete with compounded drugs and regain market share.</answer>